Evidence map›Paper›PMID 42461725›Full record

ArticleCell reports2026

ABL kinase inactivation induces transcription-replication conflicts and impairs replication fork progression in metastatic small cell lung cancer.

Jing Jin Gu, Kevin M Scott, Arijit Ghosh, Roberto H Barbier, Douglas C Rouse, Jacob P Hoj, Michael W Caminear, Fengqi Zhang, Boya Gao, Margaret W Barbier and 3 more

Abstract read
In one paragraph

Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jing Jin GuDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA.
Kevin M ScottDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA.
Arijit GhoshDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA.
Roberto H BarbierDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA.
Douglas C RouseDivision of Laboratory Animal Resources, Duke University School of Medicine, Durham, NC, USA.
Jacob P HojDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA.
Michael W CaminearDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA.
Fengqi ZhangDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA.
Boya GaoDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA.
Margaret W BarbierDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA.
Lee ZouDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA.
Li LanDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA.
Ann Marie PendergastDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC, USA. Electronic address: ann.pendergast@duke.edu.

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI Laura Fish · 1985 to 2026
$174.8M
Understanding and targeting the DNA replication stress in cancer cellsR35CA263934 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Lee Zou · 2021 to 2026
$5.2M
Targeting tumor-neural cell interactions to inhibit lung cancer brain metastasisR01CA246133 · NCI · DUKE UNIVERSITY · PI PENDERGAST, ANN MARIE · 2021 to 2025
$2.2M
Understanding and Targeting the R-Loop-Mediated DNA Damage Response at TelomeresR01CA282939 · NCI · DUKE UNIVERSITY · PI Li Lan · 2023 to 2026
$1.5M
Leica Stellaris Confocal for a Campus-wide Shared ResourceS10OD034340 · OD · DUKE UNIVERSITY · PI CAMERON, LISA A. · 2024 to 2024
$686k
ABL kinase signaling networks regulate Transcription-Replication Collisions in Small Cell Lung CancerR01CA318002 · NCI · DUKE UNIVERSITY · PI Li Lan, Ann Marie Pendergast · 2026 to 2026
$646k
PI3K-gamma signaling as a therapeutic vulnerability of POU2F3+ small cell lung cancerF30CA301871 · NCI · DUKE UNIVERSITY · PI Margaret Weber · 2025 to 2026
$86k
ABL kinase inhibition sensitizes SCLC to dysregulation of metabolic pathways leading to cell deathF31CA290817 · NCI · DUKE UNIVERSITY · PI BARBIER, ROBERTO HUGO · 2024 to 2025
$84k
Role of ABL Kinase Signaling Networks in the Regulation of Cholesterol Homeostasis in Lung CancerF31CA301550 · NCI · DUKE UNIVERSITY · PI CAMINEAR, MICHAEL WILLIAM · 2025 to 2025
$43k
NCI NIH HHS F30 CA301871NCI NIH HHS F31 CA290817NCI NIH HHS F31 CA301550NCI NIH HHS P30 CA014236NCI NIH HHS R01 CA246133NCI NIH HHS R01 CA282939NCI NIH HHS R01 CA318002NCI NIH HHS R35 CA263934NIH HHS S10 OD034340
6 · The paper itself

Abstract

Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine cancer that is typically metastatic upon diagnosis and has poor overall survival. Here we report that the inactivation of ABL tyrosine kinases impairs the outgrowth of metastatic SCLC tumors, resulting in prolonged animal survival. ABL inactivation increases the accumulation of transcription-replication conflicts (TRCs), compromises replication fork progression, and impairs the function of proteins implicated in transcription-coupled homologous recombination, including RAD51 and RAD52. Mechanistically, ABL-mediated tyrosine phosphorylation of RAD52 and RAD51 prevents the accumulation of TRCs and promotes replication fork progression, respectively. Because ABL inactivation increased DNA damage, we evaluated whether blocking the activity of DNA damage-repair pathways in the presence of ABL inhibitors might synergize to promote SCLC cell death. Concurrent inactivation of ABL and ATR, the primary responder to replication stress, synergistically inhibits SCLC cell growth in vitro and impairs metastatic outgrowth over single-agent-treated mice. Thus, co-inactivation of ABL and DNA damage-repair pathways might be exploited to inhibit outgrowth of SCLC metastases.

Indexed as

DNA ReplicationLung NeoplasmsProto-Oncogene Proteins c-ablSmall Cell Lung CarcinomaTranscription, GeneticAnimalsCell Line, TumorDNA DamageDNA RepairHumansMiceNeoplasm MetastasisPhosphorylationRad51 RecombinaseProto-Oncogene Proteins c-ablRad51 Recombinaseabl kinaseCP: cancerCP: molecular biologydna damage-repairmetastasisreplication forkssmall cell lung cancertranscription-replication conflicts

Identifiers

PMID42461725
PMCPMC13479708

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.